TikoMed
Pre-clinicalWe develop ILB®, a novel molecule that has demonstrated unique properties in stimulating the body’s own repair mechanisms in e.g. neurodegenerative conditions.
Founded
2005
Focus
Small MoleculesCell & Gene Therapy
About
We develop ILB®, a novel molecule that has demonstrated unique properties in stimulating the body’s own repair mechanisms in e.g. neurodegenerative conditions.
Funding History
2Total raised: $16.2M
Grant$1.2MVinnovaSep 15, 2020
Series A$15MIndustrifondenMay 15, 2019
Company Info
TypePrivate
Founded2005
LocationVästra Frölunda, Sweden
StagePre-clinical
Contact
SIMILAR COMPANIES
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
Phase 1 · Stockholm
Abliva
Pre-clinical · Lund
Affibody
Phase 1 · Solna
Alligator Bioscience
Phase 1 · Lund
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile